AMT-130 gets FDA breakthrough therapy designation
Amsterdam-based uniQure NV’s gene therapy candidate AMT-130 has been granted FDA Breakthrough Therapy Designation for the treatment of the neurodegenerative Huntington’s disease.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2170 entries already.
Entries by Thomas Gabrielczyk
BioSpring announces €100+m investment in new synthetic nucleic acid facility
BioSpring GmbH has broken found for one of the world’s largest production facilities for pharmaceutical nucleic acid-based therapeutics. The new high-tech plant will significantly expand the company’s manufacturing capacity for RNA- and DNA-based active pharmaceutical ingredients, and will support Good Manufacturing Practice (GMP)-compliant production for large-scale projects on behalf of BioSpring’s global partners.
MoonLake in US$500m debt deal with Hercules Capital
Swiss MoonLake Immunotherapeutics AG has secured up to US$500m in non-dilutive financing from life sciences debt specialist Hercules Capital to finance the potential 2027 launch of sonelokimab in hidradenitis suppurativa and clinical trials of the IL-17 dimerisation blocker in palmoplantar pustulosis and other inflammatory indications.
EU bioeconomy strategy enters crucial phase
Europe’s decision on how to combine economic growth and decarbonisation in the future depends on the renewal of the EU bioeconomy strategy. The question is whether the EU will fall further behind globally or whether bioeconomy will become the EU’s growth engine.
EMA set to simplify biosimilar approval
The EMA has asked the industry to share their thoughts on its draft guidelines for developing and assessing biosimilars. The idea is to make it easier for patients in the EU to get access to biosimilars, while also keeping Europe a good choice for developers.
SLAS selects 12 most innovative automation start-ups
The Society for Laboratory Automation and Screening (SLAS) has selected 12 start-ups to exhibit at Europe’s premier automation conference as part of its Innovation AveNew programme at SLAS Europe 2025, which takes place from 20-22 May in Hamburg, Germany.
New drug kills mosquitos by blood poisoning
A drug named nitisinone, EU-approved for the treatment of metabolic diseases, also shows strong mosquito-killing properties. According to researchers headed by Lee Haines, it turns human blood toxic to Anopheles mosquitoes that transmit Plasmodium falciparum, the most deadly form of malaria.
Researchers crack the code of protein degradation
Researchers at the Max Planck Institute of Biochemistry (MPIB) and MRC Laboratory of Molecular Biology in Cambridge have developed and patented the new UbiREAD technology, which decodes the complex ubiquitin code that marks target proteins for E3 ligase-mediated degradation in cells.
Augustine Therapeutics NV raises €78m in Series A round
Leuven-based Augustine Therapeutics NV will use the proceeds from a €77.7m in Series A financing led by Novo Holdings and Jeito Capital to advance its preclinical HDAC6 inhibitor AGT-100216 for the treatment of Charcot-Marie-Tooth (CMT) disease to Phase I testing.
UK to boost scale-up of biomanufacturing infrastructure
The House of Lords Science and Technology Committee wants to improve technology transfer in industrial biotechnology through better regulation, more funding, and improved access to scale-up infrastructure for biomanufacturing and bioengineering start-ups.